National Agreement for Multi-Specialty Practices & Healthcare Institutions
NEW HOPE, Pa.–(BUSINESS WIRE)–#CBD–VerdePharmHealth today announced the signing of an exclusive national group purchasing agreement with Greene Street Pharmaceuticals that will utilize proprietary CBD-Cubed™ transdermal 24-hour delivery technology for multi-specialty patients. Both organizations aim to educate healthcare providers with best-in-class cannabinoid delivery options, simplify the supply chain, and reduce costs to meet the needs of the providers and patients.
“Transdermal patches have many advantages over alternative routes of administration and have been shown to improve patient adherence, as well as maintain a steady concentration in the bloodstream. Recognizing these benefits, Greene Street Pharmaceuticals established a proprietary transdermal technology patch to expand cannabidiol delivery options for patients, with plans to continue development of novel products in collaboration with our healthcare provider network,” said Nikko Khazana, R.Ph., chief commercial officer at VerdePharmHealth. “We are extremely enthusiastic about our strategic partnership with Greene Street Pharmaceuticals, which underscores our commitment to best-in-class products to our physician network and their patients.”
“The CBD-Cubed™ technology provides precise, steady, and sustained-release transdermal delivery of cannabidiol (CBD) via a proprietary platform that combines adhesive and enhancer technology that is tested using FDA recommended methodology, to deliver product in an elegant, simple to use and comfortable to wear patch. The technology enables efficient delivery of a wide range of cannabidiol compounds, as well as our other products, that are entering clinical trials, for indications such as Alzheimer’s, Autism, Rheumatoid Arthritis and Muscle pain,” said Frank C. Jones, chief executive officer, Greene Street Pharmaceuticals. “With our commitment to the nation’s premier medical-cannabis group purchasing organization, we believe this partnership will be an improved option over other offerings that have reduced bio-availabilities and adherence issues.”
Both companies will additionally partner around observational studies to support real world use paradigms, with product made available through Santiste Labs LLC, the exclusive provider and science driven leader in transdermal delivery of cannabidiol.
VerdePharmHealth, the first organization of its kind in the U.S., provides comprehensive multi-specialty group purchasing, clinical solutions, and healthcare technology designed to drive high-level commitment and affordability for members through accessibility of quality cannabis products from prequalified manufacturers and leveraging of clinical services and robust technology to improve decisions for interventions at the point of care and capture real-world evidence. Utilizing retrospective data and clinical studies for decision-support and standardization of appropriate-use in the care delivery process is a central pillar towards achieving outcomes. For more information, visit www.verdepharmhealth.com or follow VerdePharmHealth on LinkedIn.
About Green Street Pharmaceuticals
Greene Street Pharmaceuticals is a unique Transdermal development and manufacturing company that develops branded products for transdermal dosing where patient compliance, reduction of side-effects and ease of dosing provides a significant improvement to patients. Our products are chosen and developed where there is a need to improve patient outcomes. Greene Street Pharmaceuticals has extensive knowledge in development and manufacturing various transdermal products for our global partners. Utilizing advanced testing and manufacturing techniques we are able to produce material that is consistent, high quality, controlled and tested prior to reaching any patient. With over 20 years’ experience in this drug delivery technique, Greene Street Pharmaceuticals continues to expand out pipeline of products that encompasses alternate drug delivery for Autism, Alzheimer’s, Schizophrenia, Rheumatoid Arthritis and Cardiac Arrhythmia. For more information, visit us at https://www.greenestreetpharma.com.
Matters discussed in this release that are not statements of historical or current facts, such as expected savings and other expected benefits to members and suppliers, as discussed herein, are “forward-looking statements” which may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of VerdePharmHealth and its subsidiaries to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that include terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to VerdePharm’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside VerdePharm’s control. Forward-looking statements speak only as of the date they are made. VerdePharm undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date.
firstname.lastname@example.org or George Raupp, Chief Operating Officer 610.937.1175
Green Street Pharmaceuticals
email@example.com or Frank Jones, Chief Executive Officer 267.261.6326